Advertisement

Search Results

Advertisement



Your search for all items matches 526 pages

Showing 151 - 200


leukemia
lymphoma

ASH 2016: Ibrutinib and TGR-1202 Combination Yields Encouraging Results in Patients With Relapsed Forms of Leukemia or Lymphoma

A combination of two targeted agents has demonstrated safety as well as encouraging signs of effectiveness in a phase I clinical trial in patients with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Davids et al reported the findings at the 58th American ...

lymphoma

Robert E. Marcus, MD, on Follicular Lymphoma: Results From the GALLIUM Trial

Robert E. Marcus, MD, of Kings College Hospital, discusses study findings on obinutuzumab-based induction and maintenance in patients with previously untreated disease (Abstract 6).

lymphoma

Steven Le Gouill, MD, PhD, on Mantle Cell Lymphoma: Final Results From the LyMa Trial (French Language Version)

Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses in French study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145).

lymphoma

Catherine Thieblemont, MD, PhD, on DLBCL: Results From the Lysa Remarc Study (French Language Version)

Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, discusses in French phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).

lymphoma

ASH 2016: KTE-C19 in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma and Transformed Follicular Lymphoma

Immune cellular therapy is a promising new area of cancer treatment. Anticancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and kill cancer cells. Moffitt Cancer Center physician-scientist Fredrick L. Locke, ...

lymphoma

Steven Le Gouill, MD, PhD, on Mantle Cell Lymphoma: Final Results From the LyMa Trial

Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger patients with mantle cell lymphoma (Abstract 145).

lymphoma

Syed A. Abutalib, MD, and Alex F. Herrera, MD, on Double-Hit and Double-Expressor Lymphomas: A Retrospective Analysis

Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Alex F. Herrera, MD, of City of Hope National Medical Center, discuss study findings that suggest allogeneic stem cell transplantation may overcome the chemoresistance of double-hit/double-expressor tumors (Abstract 830).

lymphoma
geriatric oncology

Catherine Thieblemont, MD, PhD, and Julie Vose, MD, MBA, on DLBCL: Results From the Lysa Remarc Study

Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).

lymphoma

Laurie H. Sehn, MD, MPH, on Follicular Lymphoma: Choosing the Best Target

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses agents in the pipeline for follicular lymphoma, including drugs targeting the immune microenvironment, novel monoclonal antibodies, and emerging immunotherapeutics.

lymphoma

Umberto Vitolo, MD, and Sagar Lonial, MD, on DLBCL: Final Results From the GOYA Trial

Umberto Vitolo, MD, of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD, of Emory University, discuss study findings on obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (Abstract 470).

lymphoma

Jonathon Cohen, MD, and Sagar Lonial, MD, on DLBCL: Results of the CALGB/Alliance 50303 Trial

Jonathon Cohen, MD, and Sagar Lonial, MD, both of Emory University, discuss study findings on R-CHOP vs DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma (Abstract 469).

lymphoma

FDA Grants sBLA to Pembrolizumab for the Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–programmed cell death protein 1 (PD-1) therapy, for the treatment of patients with refractory classical Hodgkin lymphoma or for...

lymphoma

Center for Leukemia and Lymphoma Research at UNMC Renamed Dr. James O. Armitage Center for Leukemia and Lymphoma Research

The University of Nebraska Board of Regents voted to rename an area of the University of Nebraska Medical Center (UNMC) in honor of a longtime professor who has made extraordinary contributions to the institution. The Center for Leukemia and Lymphoma Research, established in 2003, was renamed by...

lymphoma

Enrollment Completed for Phase III ECHELON-2 Clinical Trial Evaluating Front-Line Brentuximab Vedotin in Mature T-Cell Lymphoma

Seattle Genetics, Inc, and Takeda Pharmaceutical Company Limited have announced completion of patient enrollment in the ECHELON-2 clinical trial. ECHELON-2 is a global phase III randomized trial evaluating brentuximab vedotin (Adcetris) as part of a front-line combination chemotherapy regimen in...

lymphoma

Daratumumab Produces Sustained Remission in a Patient With Refractory Extranodal NK Cell–T-Cell Lymphoma

In a letter to the editor in The New England Journal of Medicine, Hari et al described a sustained response to the anti-CD38 antibody daratumumab (Darzalex) in a patient with relapsed, refractory nasal-type extranodal natural killer (NK) cell–T-cell lymphoma. In September 2014, a 56-year-old ...

lymphoma

Poorer Outcomes Reported After ASCT in Double-Hit and Double-Expressor Relapsed and Refractory Lymphomas

Patients with double-hit and double-expressor relapsed/refractory diffuse large B-cell lymphomas have poorer outcomes after autologous stem cell transplantation (ASCT), according to the findings of a retrospective analysis reported by Herrera et al in the Journal of Clinical Oncology. Double-hit...

lymphoma

Study Finds Increased Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients

In the HIV-negative population, there is growing evidence suggesting that chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) are both associated with the development of non-Hodgkin lymphoma (NHL), although the mechanisms underlying this association remain unclear. The incidence rate of NHL ...

lymphoma

Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate (Italian Language Version)

Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses in Italian high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)

lymphoma

Impact of Severe Fatigue on Treatment Outcome and Social Reintegration in Hodgkin Lymphoma

Severe cancer-related fatigue was associated with poorer clinical outcomes in patients receiving standard therapies for Hodgkin lymphoma and poorer social reintegration, according to an analysis of data from German Hodgkin Study Group trials reported in the Journal of Clinical Oncology by Behringer ...

lymphoma

Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate

Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)

lymphoma

Richard T. Hoppe, MD, on Lymphoma: Improving Outcomes

Richard T. Hoppe, MD, of Stanford University, summarizes a session on improving outcomes by enhancing old and new indications in follicular lymphoma and Hodgkin lymphoma. (Scientific Session 5)

lymphoma

Electronic Health Record Data May Help Identify Older Patients at Highest Risk of Early Death From Chemotherapy for Diffuse Large B-Cell Lymphoma

Although diffuse large B-cell lymphoma (DLBCL) is a curable disease in most patients aged 65 years or older, these patients are also at higher risk of chemotherapy-related death within the first 30 days of treatment. To quantify the risk of early fatality and identify risk factors, researchers led ...

hematologic malignancies
lymphoma

Higher Baseline Metabolic Tumor Volume May Predict Poorer Outcome in Patients With High Tumor Burden Follicular Lymphoma

In a pooled analysis reported in the Journal of Clinical Oncology, Meignan et al found that higher baseline total metabolic tumor volume measured by 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography–computed tomography (FDG PET-CT) was associated with poorer outcome in patients...

lymphoma

FDA Grants Orphan Drug Designation to CD4CAR for the Treatment of Peripheral T-Cell Lymphoma

iCell Gene Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). William Tse, MD,...

lymphoma

Identification of Genetic Variants Associated With Extranodal Natural Killer T-Cell Lymphoma

In a genome-wide association study reported in The Lancet Oncology, Li et al identified genetic variants associated with the risk of nasal-type extranodal natural killer T-cell lymphoma (NKTCL). This rare aggressive malignancy is seen predominantly in Asian and Latin American populations;...

hematologic malignancies
lymphoma

High Cumulative Burden of Cardiovascular Morbidity in Young Survivors of Hodgkin Lymphoma

In an analysis from the St. Jude Lifetime Cohort Study reported in The Lancet Oncology, Bhakta et al found a high cumulative burden of cardiovascular morbidity among pediatric, adolescent, and young adult survivors of Hodgkin lymphoma. Study Details The study involved data from 670 survivors of...

lymphoma

Is Nivolumab Active in Classical Hodgkin Lymphoma After Failure of Autologous SCT and Brentuximab Vedotin?

Treatment with the anti–PD-1 (programmed cell death protein 1) immune checkpoint inhibitor nivolumab (Opdivo) produced response in two-thirds of patients with classical Hodgkin lymphoma after failure of both autologous stem cell transplantation (SCT) and brentuximab vedotin (Adcetris),...

lymphoma

James O. Armitage, MD, on Improving Lymphoma Treatment

James O. Armitage, MD, of the University of Nebraska Medical Center, discusses how an increased understanding of the biology of lymphomas and their multiple subtypes has had a major impact on the ability to treat patients.

lymphoma

Nathan Fowler, MD, and Sagar Lonial, MD, on Treating Follicular Lymphoma

Nathan H. Fowler, MD, of University of Texas MD Anderson Cancer Center, and Sagar Lonial, MD, of the Emory University School of Medicine, discuss managing early relapsing/refractory disease.

lymphoma

Steven P. Treon, MD, PhD, on Treating Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia

Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.

lymphoma

Jonathan W. Friedberg, MD: Marginal Zone Lymphoma Therapy Update

Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of novel agents, and some possible explanations for the small subset of patients with inferior outcomes.

lymphoma

Steven M. Horwitz, MD, on Sequencing New Agents in Relapsed Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, reviews the data supporting current treatment approaches for T-cell lymphomas and discusses the specific subtype criteria used to individualize therapy.

lymphoma

Richard I. Fisher, MD, on Defining and Treating Grey Zone Lymphoma

Richard I. Fisher, MD, of Fox Chase Cancer Center-Temple Health, discusses this rare disease––with features between classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma––and reviews the clinical data on treatment.

lymphoma

Wyndham H. Wilson, MD, PhD, on Treating Diffuse Large B-Cell Lymphoma

Wyndham H. Wilson, MD, PhD, of the National Cancer Institute, discusses the molecular underpinnings of diffuse large B-cell lymphoma and targeted treatments.

lymphoma

Fredrick B. Hagemeister, Jr, MD, on Using Rituximab Maintenance

Fredrick B. Hagemeister, Jr, MD, of the University of Texas MD Anderson Cancer Center, discusses whether rituximab maintenance should be used in indolent lymphomas other than follicular.

lymphoma

John G. Gribben, MD, DSc, on Follicular Lymphoma: Still a Role for Transplant?

John G. Gribben, MD, DSc, of Barts Cancer Institute, discusses the pros and cons of both autologous and allogeneic stem cell transplantation in follicular lymphoma, and the challenges of selecting the right patients for these procedures.

lymphoma

Julie M. Vose, MD, MBA, on Highlights of Pan Pacific Lymphoma 2016

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.

lymphoma

Bruce D. Cheson, MD, and Julie M. Vose, MD, MBA, on Staging Lymphoma

Bruce D. Cheson, MD, of Georgetown University Hospital, and Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discuss whether lymphoma should be staged with a positron emission tomography (PET) scan and what follow-up scans are needed.

lymphoma

David G. Maloney, MD, PhD, on Lymphomas: Treatment With CAR T Cells

David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses the efficacy of chimeric antigen receptor (CAR) T cells for lymphoma and their toxicity.

lymphoma

Stephen M. Ansell, MD, PhD, on Precision Immunotherapy for Refractory Hodgkin Lymphoma

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.

leukemia
lymphoma

Susan M. O’Brien, MD, on ALL/Lymphoma: Upfront and Salvage Treatments in Older Patients

Susan M. O’Brien, MD, of the University of California, Irvine, discusses the challenges of treating older patients with acute lymphoblastic leukemia and lymphoma, and the positive results with newer regimens using blinatumomab and inotuzumab.

lymphoma

Kieron M. Dunleavy, MD, on Lymphomas: Genomics and Genetics

Kieron M. Dunleavy, MD, of the National Cancer Institute, discusses the genomic landscape of aggressive lymphomas and how this is informing therapy decisions.

lymphoma

Andrew D. Zelenetz, MD, on Diffuse Large B-Cell Lymphoma: CHOP-R and EPOCH-R?

Andrew D. Zelenetz, MD, of Memorial Sloan Kettering Cancer Center, discusses the pros and cons of these two regimens, with or without another agent, in diffuse large B-cell lymphoma.

lymphoma

Five-Year Survival Data: Brentuximab Vedotin May Be Curative in Some Patients With Hodgkin Lymphoma

Five-year survival data published by Chen et al in Blood suggest that the targeted therapy brentuximab vedotin (Adcetris) may be curative in some patients with Hodgkin lymphoma whose disease has persisted despite receiving previous therapies. This multinational phase II study examined brentuximab...

hematologic malignancies
lymphoma

CNS-IPI for CNS Relapse in Diffuse Large B-Cell Lymphoma

As reported in the Journal of Clinical Oncology, Schmitz et al have developed and validated a risk score for CNS relapse—the Central Nervous System International Prognostic Index (CNS-IPI)—in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab [Rituxan]...

hematologic malignancies
lymphoma

Analysis Indicates Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage DLBCL

In an analysis of data from SWOG studies reported in the Journal of Clinical Oncology, Stephens et al found as continued risk of relapse among patients with limited-stage diffuse large B-cell lymphoma (DLBCL) irrespective of whether they received CHOP (cyclophosphamide, doxorubicin, vincristine,...

hematologic malignancies
lymphoma

Early Results Find Pembrolizumab Active in Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Findings in a classical Hodgkin lymphoma cohort in the phase Ib KEYNOTE-013 trial, reported by Armand et al in the Journal of Clinical Oncology, indicate that pembrolizumab (Keytruda) is active in patients with disease progressing on or after brentuximab vedotin (Adcetris) treatment. Study Details ...

lymphoma

Comparison of Chemotherapy Regimens After Negative Interim PET-CT in Advanced Hodgkin Lymphoma

In a phase III trial reported in The New England Journal of Medicine, Johnson et al found similar efficacy with continued ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy vs omission of bleomycin (AVD) after negative interim PET-CT (positron-emission tomography–computed...

hematologic malignancies
lymphoma

Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL

In the phase III GADOLIN trial reported in The Lancet Oncology, Sehn et al found that adding the anti-CD20 antibody obinutuzumab (Gazyva) to bendamustine (Bendeka, Treanda) increased progression-free survival in patients with rituximab-refractory indolent non-Hodgkin lymphoma (NHL). Outcomes in...

lymphoma

Study Finds Addition of High-Dose Cytarabine to Immunochemotherapy Before Transplant Improves Outcomes in Younger Patients With MCL

The phase III European MCL Younger trial has shown that adding high-dose cytarabine to immunochemotherapy prior to autologous stem cell transplantation (ASCT) increased the time to treatment failure among patients with mantle cell lymphoma (MCL) aged ≤ 65 years. The results were reported by...

Advertisement

Advertisement



;
Advertisement